Table 1

Baseline characteristics of the patients, overall and in each treatment group

Total

n.49

Exposure to TDF

Exposure to concomitant use of TDF and PI


A

TDF

n.31 (63%)

B

NO TDF

n.18 (37%)

p

C

TDF+PI

n.23 (47%)

D

NO TDF+PI

n.26 (53%)

p


Female n (%)

28 (57%)

18 (58%)

10 (56%)

0.86

12 (52%)

16 (62%)

0.51


Age Mean (SD)

13.6 (± 2.5)

14.0

13.0

0.18

14.1 (± 2.7)

13.2(± 2.3)

0.20


HIV < 50 copies/mL

23 (47%)

12 (39%)

11 (61%)

0.13

9 (39%)

14 (54%)

0.30


CD4% (SD)

27.1 (± 10.2)

24.7 (± 10.4)

31.8 (± 8.3)

0.04

23.6 (± 10.5)

30.7 (± 8.8)

0.02


Ethnicity (Africa)

8 (16%)

3 (10%)

5 (28%)

0.10

2(9%)

6 (23%)

0.17


eGFR at baseline median ml/min per 1.73 m2(IQR)

143.6 (124.5-167.4

143.6 (123.7-165.4)

147.5 (124.5-169.6)

0.48*

135.0 (122.2-156.0)

152.6 (128.0-169.6)

0.14*


Phosphatemia at baseline Median mg/dl (IQR)

4.4 (3.8-5.0)

4.4 (3.8-5.0)

4.7 (3.8-5.2)

0.30*

4.4 (3.9-5.0)

4.5 (3.8-5.1)

0.44*


Years on current regimen mean (SD)

1.11 (1,64)

0,76 (1,30)

1,71 (1,99)

0.06

1 (1,41)

1,21 (1,84)

0.67


ART regimen

TDF+FTC+LPV/r

10 (20%)

10 (32%)

-

-

10 (43%)

-

TDF+FTC+ATV/r

11 (22%)

11 (35%)

-

-

11 (48%)

-

TDF+FTC+Other PI/r

2 (4%)

2 (6%)

-

-

2 (9%)

-

ABC+3TC+LPV/r

6 (12%)

-

6 (33%)

-

-

6 (23%)

-

ABC+3TC+other PI

4 (8%)

-

4 (22%)

-

-

4 (15%)

-

3TC+ABC+EFV

7 (14%)

-

7 (39%)

-

-

7 (27%)

-

ABC+3TC+AZT

1 (2%)

-

1 (6%)

-

-

1 (4%)

-

TDF+ABC+EFV

1 (2%)

1 (3%)

-

-

-

1 (4%)

-

TDF+FTC+EFV

7 (14%)

7 (23%)

-

-

-

7 (27%)

-


SD Standard Deviation; p value calculated with ANOVA or with Mann Whitney test (*) and was referred to comparison between baseline variable of Group A versus Group B, or Group C versus Group D. TDF Tenofovir Disoproxil Fumarate; FTC= Emtricitabine; LPV/r = Lopinavir/ritonavir; ATV/r Atazanavir/ritonavir; PI/r= Ritonavir boosted Protease Inhibitors; ABC= Abacavir; 3TC= Lamivudine; EFV= Efavirenz; AZT= Zidovudine; OT Other Treatments; r= ritonavir; IQR interquartile range

Pontrelli et al. BMC Infectious Diseases 2012 12:18   doi:10.1186/1471-2334-12-18

Open Data